See at right, but here is what Abbott Labs lobbied about:
. . .S. 2477/H.R. 1770 Equitable Community Access to Pharmacist Services Act; S. 2922 Advancing Research for Chronic Pain Act of 2023; H.R. 2369 Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023; Proposals related to sterilization of medical devices; Proposals related to the President's Emergency Plan for AIDS Relief (PEPFAR); Proposals related to Department of Defense coverage of continuous glucose monitors; Proposals to advance policies related to effective pain management; Proposals related to future pandemic preparedness; Proposals related to the advancement, testing, and detection of Traumatic Brain Injury; Proposals related to the safe manufacturing of medical devices; Proposals related to the use of diagnostic tests in CLIA-waived settings. . . .
S. 1000/H.R. 1835 Saving Access to Laboratory Services Act; H.R.3674 Providing Relief and Stability for Medicare Patients Act of 2023; Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule; Proposals related to Medicare coverage of continuous glucose monitors; Proposals related to outpatient coverage of cardiovascular medical devices. . . .
Proposals related to U.S. global health programs and pandemic preparedness; Proposals to advance global virus surveillance; Proposals related to preserving critical medical supply chains; Proposals regarding infant and child nutrition marketing. . . .Proposals related to access to infant formula. . . . [This is spending related to a very old (since 1950s) legacy Abbott brand (Ross Labs). . . .]
Now you know -- And. . . . my exacta box bet is now down, at Churchill Downs -- let's see how they all break!
नमस्ते
No comments:
Post a Comment